Impact of Medication Adherence on the Effect of Renal Denervation: The SYMPATHY Trial

Hypertension

Volumn 69, Issue 4, 2017, Pages 678-684

  De Jager, Rosa L ^a   De Beus, Esther ^a   Beeftink, Martine M A ^b   Sanders, Margreet F ^a   Vonken, Evert Jan ^b   Voskuil, Michiel ^b   Van Maarseveen, Erik M ^b   Bots, Michiel L ^a   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Cardiology ^*  (Netherlands)

Author keywords

blood pressure; meta analysis; randomized controlled trial; renal denervation; sympathetic nervous system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN INHIBITOR; SPIRONOLACTONE;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CATHETER ABLATION; CLINICAL TRIAL; HYPERTENSION; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; SYMPATHECTOMY; TIME FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; SYMPATHECTOMY; TIME FACTORS; TREATMENT OUTCOME;

EID: 85014575969     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08818     Document Type: Article

References (24)

1. Azizi M, Sapoval M, Gosse P, et al; Renal Denervation for Hypertension (DENERHTN) Investigators. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385:1957-1965. doi: 10.1016 S0140-6736(14)61942-5.
2. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401. doi: 10.1056/NEJMoa1402670.
3. Desch S, Okon T, Heinemann D, Kulle K, Röhnert K, Sonnabend M, Petzold M, Müller U, Schuler G, Eitel I, Thiele H, Lurz P. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65:1202-1208. doi: 10.1161 HYPERTENSIONAHA.115.05283.
4. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-1909.
5. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63:991-999. doi: 10.1161 HYPERTENSIONAHA.114.03246.
6. Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, Haskin R, Negoita M, Shimada K; SYMPLICITY HTN-Japan Investigators. SYMPLICITY HTN-Japan - first randomized controlled trial of catheterbased renal denervation in Asian patients. Circ J. 2015;79:1222-1229. doi: 10.1253/circj.CJ-15-0150.
7. Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study. Hypertension. 2015;65:407-413. doi: 10.1161 HYPERTENSIONAHA.114.04019.
8. Mathiassen ON, Vase H, Bech JN, et al. Renal denervation in treatmentresistant essential hypertension. A randomized, SHAM-controlled, doubleblinded 24-h blood pressure-based trial. J Hypertens. 2016;34:1639-1647. doi: 10.1097/HJH.0000000000000977.
9. Blankestijn PJ, Alings M, Voskuil M, Grobbee DE. The complexity after simplicity: how to proceed with renal denervation in hypertension? Eur J Prev Cardiol. 2015;22:412-414. doi: 10.1177/2047487314538859.
10. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219-227. doi: 10.1093/eurheartj/ehu441.
11. Persu A, Jin Y, Fadl Elmula FE, Jacobs L, Renkin J, Kjeldsen S. Renal denervation after SYMPLICITY HTN-3: an update. Curr Hypertens Rep. 2014;16:460. doi: 10.1007/s11906-014-0460-x.
12. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, Toennes SW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766-774. doi: 10.1097 HJH.0b013e32835e2286.
13. Strauch B, Petrák O, Zelinka T, Rosa J, Somlóová Z, Indra T, Chytil L, Marešová V, Kurcová I, Holaj R, Wichterle D, Widimský J Jr. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31:2455-2461. doi: 10.1097 HJH.0b013e3283652c61.
14. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, Samani NJ, Gupta P, Madira W, Stanley A, Williams B. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100:855-861. doi: 10.1136/heartjnl-2013-305063.
15. Vink EE, de Beus E, de Jager RL, Voskuil M, Spiering W, Vonken EJ, de Wit GA, Roes KC, Bots ML, Blankestijn PJ. The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: rationale and design of the SYMPATHY trial. Am Heart J. 2014;167:308.e3-314. e3. doi: 10.1016/j.ahj.2013.11.010.
16. Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML, Doevendans PA, Blankestijn PJ, Spiering W. Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens. 2013;31:1662-1668. doi: 10.1097/HJH.0b013e328362152e.
17. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
18. Papademetriou V, Tsioufis CP, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Worthley MI, Worthley SG. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system. Hypertension. 2014;64:565-572. doi: 10.1161/HYPERTENSIONAHA.114.03605.
19. Olah TV, McLoughlin DA, Gilbert JD. The simultaneous determination of mixtures of drug candidates by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry as an in vivo drug screening procedure. Rapid Commun Mass Spectrom. 1997;11:17-23. doi: 10.1002/(SICI)1097-0231(19970115)11:117::AID-RCM8123.0.CO;2-N.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. doi: 10.1056/NEJMra050100.
21. Schmieder RE. Renal denervation-A valid treatment option despite SYMPLICITY HTN-3. Nat Rev Cardiol. 2014;11:638. doi: 10.1038 nrcardio.2014.70-c2.
22. Azizi M, Pereira H, Hamdidouche I, et al; DENERHTN Investigators. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation. 2016;134:847-857. doi: 10.1161 CIRCULATIONAHA.116.022922.
23. Ewen S, Meyer MR, Cremers B, Laufs U, Helfer AG, Linz D, Kindermann I, Ukena C, Burnier M, Wagenpfeil S, Maurer HH, Böhm M, Mahfoud F. Blood pressure reductions following catheterbased renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol. 2015;104:1097-1105. doi: 10.1007 s00392-015-0905-5.
24. Schmieder RE, Ott C, Schmid A, Friedrich S, Kistner I, Ditting T, Veelken R, Uder M, Toennes SW. Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;5:e002343. doi: 10.1161/JAHA.115.002343.